Editas Medicine Inc (EDIT) Stock Forecast & Price Target
Editas Medicine Inc · NASDAQ
$3.03-0.20 (-6.19%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Editas Medicine Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $4.00 to $8.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $6.00 sits 98% above the current $3.03. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.21 next quarter toward $-0.75 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Editas Medicine Inc.
As of Sep, 3 of 3 firms rate EDIT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
EDIT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.21
Range $-0.28 – $-0.08 · 7 analysts · +248% YoY
Next period, 7 analysts expect Editas Medicine Inc to earn $-0.21 a share (range $-0.28 – $-0.08), versus $-0.06 a year earlier. Full-year consensus is $-0.83, growing to $-0.75 the year after.
REVENUE · NEXT QUARTER
$6.7M
Range $1.0M – $20.0M · 7 analysts · -73% YoY
Revenue is expected to reach $6.7M (range $1.0M – $20.0M), -73.1% year-over-year. Full-year consensus is $25.9M, rising to $19.4M next year.
Top analysts covering Editas Medicine Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EDIT.
#1
Luca Issi
RBC Capital · Rank #1
Hold
$4.00+32.0% to target
Overall win rate
55%
+ Follow
#2
Joel Beatty
Baird · Rank #80
Buy
$6.00+98.0% to target
Overall win rate
48%
+ Follow
#3
Geulah Livshits
Chardan Capital · Rank #85
Buy
$4.00+32.0% to target
Overall win rate
46%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$5.00+65.0% to target
Overall win rate
34%
+ Follow
#5
Yanan Zhu
Wells Fargo
Hold
$4.00+32.0% to target
Coverage
—
+ Follow
EDIT stock forecast FAQ
What is EDIT's average 12-month price target?+
The 2 analysts with a live target average $6.00 for Editas Medicine Inc over the next 12 months, ranging from a $8.00 high to a $4.00 low.
Is EDIT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for EDIT?+
The Street-high target is $8.00 (Jones Trading), and the Street-low is $4.00 (Chardan Capital). The average of all 2 active targets is $6.00.
How many Wall Street analysts cover EDIT?+
3 analysts have an active rating on Editas Medicine Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering EDIT?+
Among analysts who currently cover EDIT, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Hold with a $4.00 target.
What is Editas Medicine Inc's projected EPS for next quarter?+
The consensus estimate is $-0.21 per share (range $-0.28 – $-0.08) across 7 analysts. Full-year EPS is projected at $-0.83, rising to $-0.75 the following year.
How much revenue is Editas Medicine Inc expected to report next quarter?+
Consensus revenue is $6.7M (range $1.0M – $20.0M). Full-year revenue is projected at $25.9M, growing to $19.4M next year.
Have analysts been upgrading or downgrading EDIT lately?+
As of Sep, 3 of 3 firms rate EDIT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EDIT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
